Following my last publication on United Therapeutics (NASDAQ: UTHR ), the stock has rallied another 11% and has taken out my previous price target. Several updates have occurred since then which are in need ofEquity strategist [Bernard Holdings]. Objective view on the directional bias of markets. Technical expertise bridges the complex relationships between value drivers, capital flows and price action. Partners are represented over the cross-section of financial markets, from speculators, hedgers, long-ter ...

United Therapeutics Corporation (NASDAQ: UTHR ) is at the forefront of innovation in the biotechnology and pharmaceutical industry. Its portfolio of FDA-approved products treats pulmonary arterial hypertension (PAH) and related cardiovascular conditions. The company's wide treatment options, including oral and injectable therapies like Orenitram, Remodulin, and Adcirca, strengthen My name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Polite ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there. The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecast ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Sc ...

Zacks Premium and Style Scores - Zacks Premium offers tools like daily updates of Zacks Rank and Zacks Industry Rank, full access to the Zacks 1 Rank List, Equity Research reports, and Premium stock screens to help investors make informed decisions [1] - Zacks Style Scores rate stocks based on value, growth, and momentum characteristics, assigning ratings from A to F, with A being the best [2][3] - The Style Scores are divided into four categories: Value Score, Growth Score, Momentum Score, and VGM Score, which combines all three styles [3][4][5] - Zacks Rank, combined with Style Scores, helps investors select stocks with the highest probability of outperforming the market [6][8] - Stocks with a Zacks Rank 1 or 2 and Style Scores of A or B offer the best chance of high returns [9][10] United Therapeutics Corporation (UTHR) - United Therapeutics markets four medicines for pulmonary arterial hypertension (PAH): Remodulin, Orenitram, Tyvaso, and Adcirca [11] - UTHR has a Zacks Rank of 3 (Hold) and a VGM Score of A, with a Value Style Score of B due to attractive valuation metrics like a forward P/E ratio of 14.7 [12][13] - Four analysts revised their earnings estimates upwards for fiscal 2024, increasing the Zacks Consensus Estimate by $0.58 to $25.44 per share, with an average earnings surprise of 4.2% [12] - UTHR is a stock to watch due to its solid Zacks Rank and top-tier Value and VGM Style Scores [13][14]

United Therapeutics’ (UTHR) third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings rose 19% year over year on the back of higher product sales.Revenues totaled $748.9 million, which beat the Zacks Consensus Estimate of $717.5 million. Revenues rose 23% year over year, driven by meaningful growth of key products — Tyvaso, Orenitram and Unituxin.See the Zacks Earnings Calendar to stay ahead of market-making news.More on UTHR’s EarningsUnited Therapeutics markets fo ...

United Therapeutics Corporation (NASDAQ:UTHR) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Joseph Thome - TD Cowen Roanna Ruiz - Leerink Partners Andre ...

United Therapeutics (UTHR) reported $748.9 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 22.9%. EPS of $6.39 for the same period compares to $5.38 a year ago.The reported revenue represents a surprise of +4.38% over the Zacks Consensus Estimate of $717.49 million. With the consensus EPS estimate being $6.18, the EPS surprise was +3.40%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...

United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 3.40%. A quarter ago, it was expected that this drugmaker would post earnings of $6.33 per share when it actually produced earnings of $5.85, delivering a surprise of -7.58%. Over the last four quarters, the c ...

Exhibit 99.1 For Immediate Release United Therapeutics Corporation Reports Third Quarter 2024 Financial Results SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., October 30, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I'm proud of the cl ...